Industrial Synthesis Route For 1,2,3,4-Tetrahydrocarbazol-4-One
- R&D Focus: Optimized Fischer indole pathways ensure process-scale purity and consistent yields exceeding 75%.
- Procurement Advantage: Factory-direct bulk price advantages with verified COA and SDS documentation for every batch.
- Executive Overview: Regulatory compliance and tonnage quantities available for commercial grade production globally.
The demand for high-performance pharmaceutical intermediates requires a robust understanding of chemical manufacturing capabilities. 1,2,3,9-Tetrahydro-4(H)-Carbazol-4-One (CAS: 15128-52-6) serves as a critical building block in the development of novel therapeutic agents. Achieving industrial purity for this compound demands precise control over reaction conditions, purification protocols, and quality assurance measures. As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. specializes in delivering this intermediate with the batch-to-batch consistency required for large-scale drug synthesis.
Optimization Strategies for Scalable Manufacturing
For process chemists, the selection of the appropriate synthesis route is paramount to maximizing yield while minimizing impurity profiles. The production of 1,2,3,4-Tetrahydro-4-oxocarbazole derivatives typically relies on optimized Fischer indole synthesis protocols. Classical literature procedures indicate that careful management of reflux temperatures and stoichiometric ratios is essential. Historical data from established organic synthesis protocols suggests that yields ranging from 76% to 85% are achievable when reaction times and cooling phases are strictly controlled.
To maintain process-scale purity, the workup procedure is just as critical as the reaction itself. Industrial best practices involve vigorous stirring during precipitation to prevent lump formation, followed by suction filtration. The crude solid often requires extensive washing with water and ethanol solutions to remove residual acids and unreacted hydrazines. Furthermore, crystallization from methanol, often aided by decolorizing carbon, ensures the removal of colored impurities and trace organics. Air-drying periods of 50 to 70 hours may be necessary to attain constant weight before final milling and packaging.
Technical Specifications and Quality Parameters
Ensuring commercial viability requires adherence to strict physical and chemical standards. The following table outlines the typical quality parameters expected for commercial grade supply of this intermediate.
| Parameter | Specification | Test Method |
|---|---|---|
| Product Name | 1,2,3,9-Tetrahydro-4(H)-Carbazol-4-One | Internal QC |
| CAS Number | 15128-52-6 | Verified |
| Purity (HPLC) | > 98.5% | Area Normalization |
| Appearance | Off-white to Light Yellow Crystalline Powder | Visual |
| Loss on Drying | < 0.5% | Karl Fischer / Oven |
| Packaging | 25kg Drum or Custom Bulk | Standard |
Procurement and Supply Chain Stability
For procurement managers, securing a reliable supply chain is essential to prevent production bottlenecks. Sourcing from a dedicated facility ensures that bulk price stability is maintained even during market fluctuations. When sourcing high-purity 1,2,3,9-Tetrahydro-4(H)-Carbazol-4-One, buyers should prioritize suppliers who provide comprehensive documentation. This includes Certificates of Analysis (COA) for every batch, Safety Data Sheets (SDS), and stability data.
Factory-direct advantages eliminate intermediary markups and reduce lead times. NINGBO INNO PHARMCHEM CO.,LTD. maintains significant inventory levels to support tonnage quantities for clinical and commercial phases. Our logistics network ensures that materials are shipped with proper hazard classification and temperature control where necessary, guaranteeing that the manufacturing process at the client site remains uninterrupted.
Regulatory Compliance and Commercial Viability
Executive decision-makers must consider regulatory landscapes such as REACH and TSCA when selecting intermediates. Our production facilities are audited to meet international safety and environmental standards. The scalability of the 1,2,3,9-Tetrahydro-4(H)-carbazol-4-one production line allows for seamless transition from pilot batches to full-scale commercial manufacturing. This reduces the risk associated with process validation during regulatory filings.
By partnering with a technically proficient supplier, pharmaceutical companies can mitigate supply risk and ensure that impurity profiles remain consistent throughout the product lifecycle. Our commitment to quality assurance supports the long-term commercial viability of your drug development pipeline.
To discuss your specific requirements, please contact our technical sales team for a batch-specific COA, SDS, or bulk pricing quote.